Differences in response to fetal hemoglobin induction therapy in β-thalassemia and sickle cell disease
- 1 July 2009
- journal article
- research article
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 43 (1) , 58-62
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Epigenetic analysis of the human α- and β-globin gene clustersBlood Cells, Molecules, and Diseases, 2008
- Role of epigenetic modifications in normal globin gene regulation and butyrate-mediated induction of fetal hemoglobinBlood, 2007
- Sickle cell disease: old discoveries, new concepts, and future promiseJournal of Clinical Investigation, 2007
- Pharmacological induction of fetal hemoglobin in sickle cell disease and β-thalassemiaSeminars in Hematology, 2001
- Hydroxyurea Therapy in ThalassemiaaAnnals of the New York Academy of Sciences, 1998
- Hydroxyurea therapy in β‐thalassaemia intermedia: improvement in haematological parameters due to enhanced β‐globin synthesisBritish Journal of Haematology, 1995
- Pharmacologic treatment of thalassemia intermedia with hydroxyureaThe Journal of Pediatrics, 1994
- Pharmacological Manipulation of Fetal Hemoglobin Synthesis in Patients with Severe β‐ThalassemiaAnnals of the New York Academy of Sciences, 1985
- 5-Azacytidine Selectively Increases γ-Globin Synthesis in a Patient with β+ThalassemiaNew England Journal of Medicine, 1982
- Fetal hemoglobin and clinical severity of homozygous sickle cell disease in early childhoodThe Journal of Pediatrics, 1981